Sex differences in the effectiveness of first-line tumor necrosis factor inhibitors in psoriatic arthritis; results from the EuroSpA Research Collaboration Network.
Pasoon HellamandMarleen G H van de SandeLykke M ØrnbjergThomas KlauschKari K EklundHeikki RelasMaria Jose SantosElsa Vieira-SousaAnne Gitte LoftBente GlintborgMikkel ØstergaardUlf LindströmJohan Karlsson WallmanBrigitte MichelsenKaren M FagerliIsabel CastrejonBjorn GudbjornssonThorvardur J LoveJiří VencovskýLucie NekvindováŽiga RotarMatija TomšičFederico Díaz-GonzálezGökce KenarHandan Y TuğsalFlorenzo IannoneRoberta RamondaCatalin CodreanuCorina MogosanMichael J NissenBurkhard MöllerMerete L HetlandIrene E van der Horst-BruinsmaPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2023)
Despite comparable disease characteristics at baseline, women with PsA have reduced treatment response and retention rates to their first TNFi, highlighting the need to consider sex differences in PsA research and management.